Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ in Dilated Cardiomyopathy
NCT05410873Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Countries
- 1
- Sponsor
- Imperial College London
- Modality
- Orthosteric Ligands
- Drugs
- mitoquinone
- Conditions
- dilated cardiomyopathy (DCM)
01
Overview
Phase 2, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing MitoQ with Placebo (2 arms). Primary endpoints: Myocardial Phosphocreatine to Adenosine Triphosphate Ratio at 3 months, Circulating Markers of Oxidative Stress at 3 months and 1 more. Started Jul 2022; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
MitoQ
Mitoquinol mesylate 40mg daily
Placebo
Placebo daily
03
Who it enrols
Patients with idiopathic or familial DCM, LVEF ≤45%, on stable guideline therapy, with elevated NT-pro-BNP and sinus rhythm.
04
Endpoints
Primary
Myocardial Phosphocreatine to Adenosine Triphosphate Ratio
Circulating Markers of Oxidative Stress
Left Ventricular End-Systolic Volume Index
Secondary
Skeletal Muscle Phosphocreatine Recovery
Left Ventricular Ejection Fraction
Left Ventricular End-Diastolic Volume Index
Global Longitudinal Strain
N-terminal pro-B-type Natriuretic Peptide
Renal Function
Symptom Burden
Exercise Capacity
Beyond the preview
Go deeper on NCT05410873.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410873.